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INTRODUCTION
Enterococci are increasingly encountered as significant
pathogens, and have become a major cause of nosocomial
infections. Moreover, multi-drug resistant enterococci includ-
ing vancomycin-resistant enterococci have emerged, and now
represent a major clinical problem (1-3). Antibiotic treatment
of diseases caused by these organisms is complicated by intrin-
sic and acquired resistance to various antibiotics. Resistances
to penicillin, vancomycin and high-level aminoglycosides
are clinically important because they limit antibiotic treat-
ment options.
A combination of cell wall active agents and aminoglyco-
sides is recommended to achieve a synergistic bactericidal
effect in enterococcal endocarditis and meningitis (4). More-
over, many infectious disease specialists use combination ther-
apy for non-endocarditis bacteremia and other serious ente-
rococcal infections, especially in critically ill patients (5, 6).
However, combination treatment is not applicable in cases
of infection caused by enterococci with high-level aminogly-
coside resistance. For this reason, it is important to establish
the risk factors of infection caused by enterococci with high-
level aminoglycoside resistance, and the influence of high-
level aminoglycoside resistance on outcome. However there
have been few clinical studies of these matters and no conclu-
sive data are available (7-12).
We performed this study to compare the clinical features
of bacteremia caused by enterococci with high-level gentam-
icin resistance (HLGR) with those of bacteremia caused by
non-HLGR enterococci, to investigate the risk factors for bac-
teremia caused by enterococci with HLGR, and to determine
whether HLGR influences outcome.
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Clinical Features, Risk Factors and Outcomes of Bacteremia due to
Enterococci with High-Level Gentamicin Resistance: Comparison with
Bacteremia due to Enterococci without High-Level Gentamicin 
Resistance
High-level gentamicin resistance (HLGR) in enterococci has increased since the
1980s, but the clinical significance of the resistance and its impact on outcome have
not been established. One hundred and thirty-six patients with bacteremia caused by
enterococci with HLGR (HLGR group) were compared with 79 patients with bactere-
mia caused by enterococci without HLGR (non-HLGR group). Hematologic malig-
nancy, neutropenia, Enterococcus faecium infection, nosocomial infection and mono-
microbial bacteremia were more common in the HLGR group than the non-HLGR
group, and APACHE II scores were also higher (P<0.05, in each case). Neutrope-
nia, monomicrobial infection, stay in intensive care at culture, and use of 3rd gen-
eration cephalosporin, were independent risk factors for acquisition of HLGR ente-
rococcal bacteremia. Fourteen-day and 30-day mortalities were higher in the HLGR
group than the non-HLGR group in univariate analysis (37% vs. 15%, P=0.001; 50%
vs. 22%, P<0.001). However, HLGR was not an independent risk factor for mortali-
ty due to enterococcal bacteremia in multivariate analysis. Therefore, HLGR ente-
rococcal bacteremia is associated with more severe comorbid conditions and high-
er mortality than non-HLGR enterococcal bacteremia but the HLGR itself does not
contribute significantly to mortality.
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Patients
All patients with positive blood cultures for Enterococcus fae-
calis and Enterococcus faecium between January 1999 and August
2003 were identified by a review of the computerized records
of the Clinical Microbiology Laboratory of Seoul National
University Hospital (Seoul, Republic of Korea), a 1500-bed
tertiary care University Hospital and referral center. Patients
of age 16 or older were included. Enterococcal bacteremia
occurring 60 days or more after a previous episode in a patient
that had already been registered was counted as a separate
case and was included in the study (13). Medical records of
the patients were retrospectively reviewed.
Microbiological tests
Enterococcus species were identified on the basis of 6.5%
NaCl tolerance, bile-esculin hydrolysis, and growth rate at
45℃. Species were identified with the Vitek system (bio-
Me@rieux, Marcy l’Etoile, France), and by tests for motility,
yellow pigmentation and methyl-a-D-glucopyranoside (14,
15). Antibiotic susceptibilities were determined by the disk
diffusion method, following the recommendations of the Clin-
ical and Laboratory Standards Institute (16). HRGR was
determined by the disk diffusion method with 120 mg gen-
tamicin discs (Oxoid Ltd., Basingstoke, UK) (16).
Definitions
Clinically significant bacteremia was defined as the isolation
of enterococci from two or more separately obtained blood
cultures, from a single blood culture and from a primary site,
or from a single blood culture with a clinically apparent pri-
mary site.
HLGR was defined as a minimal inhibitory concentration
of gentamicin exceeding 500 mg/mL (16).
Polymicrobial bacteremia was defined as the isolation from
blood culture of one or more species of bacteria in addition
to the enterococci (the same blood culture, or another blood
culture within 24 hr of the initial culture that yielded ente-
rococci). A single concomitant isolation of another bacterial
species was deemed sufficient, except for coagulase-negative
staphylococci, diphtheroids, a-hemolytic streptococci, and
Bacillus species, which required isolation from two blood cul-
tures.
Enterococcal bacteremia was considered to have been of
community-onset if the enterococci were isolated from cultures
of blood samples obtained within 48 hr of hospital admission
(if the patient had not been transferred from another hospi-
tal), and if the patient had symptoms or signs suggestive of
infection on admission. Otherwise, the enterococcal bacteremia
was considered to be nosocomial.
Appropriate antibiotic treatment was defined as the use of one
or more active antibiotic to which the organism was suscep-
tible in vitro within five days of the date on which a positive
blood culture was obtained (17). Antibiotics considered active
included penicillin, ampicillin, piperacillin, vancomycin,
teicoplanin, quinupristin-dalfopristin and linezolid.
Neutropenia was defined as a neutrophil count of <500 cells/
mL or a count of ≤1,000 cells/mL with a predicted decrease
to <500 cells/mL. 
Statistical analyses
Categorical variables were compared using Fisher’s exact
test or Pearson chi-square test, as appropriate, and continuous
variables were compared using the Student’s t test. All tests
of significance were 2-tailed, and P≤0.05 was considered sig-
nificant. Logistic regression analysis was carried out to deter-
mine the risk factors for acquisition of bacteremia caused by
enterococci with HLGR, and Cox-regression survival analy-
sis was used to determine the independent risk factors for out-
come of enterococcal bacteremia. Variables that were not sig-
nificant in the univariate analysis (P>0.05) were excluded
from the multivariate analysis. Multivariate analysis was per-
formed in the backward stepwise conditional manner. Statis-
tical analyses of the data were performed with SPSS for Win-
dows (version 11.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Enterococcus species in blood isolates
We identified 215 cases of clinically significant E. faecalis
and E. faecium bacteremia. One hundred and fifty (70%) were
caused by E. faecium and 65 (30%) by E. faecalis. One hun-
dred and thirty six (63%) were caused by enterococci with
HLGR and 79 (37%) by enterococci without HLGR. The
HLGR rate was 70% (105/150) in E. faecium and 48% (31/
65) in E. faecalis.
Enterococci were isolated from two or more separately ob-
tained blood cultures in 113 (53%) cases, from a single blood
culture and from a primary site in 40 (19%) cases, and from
a single blood culture with a clinically apparent primary site
in 62 (29%) cases. Eight patients (two with E. faecalis, six
with E. faecium) were re-enrolled because bacteremia caused
by the same organism occurred again after 60 days.
Clinical features of patients with bacteremia caused by
HLGR
The demographic, clinical features and outcomes of each
group are shown in Table 1. The most common underlying
disease in both groups was cancer, accounting for approxima-
tely 50% of cases. Two hundred six of the cases (96%) were
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(4%) of endocarditis and no cases of meningitis were detected.
Hematologic malignancy, neutropenia, E. faecium infection,
monomicrobial bacteremia and nosocomial infection were
significantly more common in bacteremia caused by entero-
cocci with HLGR than in bacteremia caused by enterococci
without HLGR (P<0.05, in each case). On the other hand,
biliary tract infection was less common in the former. Mean
acute physiology and chronic health evaluation (APACHE)
II scores were higher in bacteremia caused by enterococci with
HLGR. Rates of resistance to ampicillin, vancomycin and
high-level streptomycin were also higher in isolates of ente-
rococci with HLGR (Table 2).
Risk factors for the acquisition of bacteremia caused by
enterococci with HLGR
We performed multivariate analysis with a logistic regres-
sion model to identify the independent risk factors for the
acquisition of bacteremia caused by enterococci with HLGR.
The multivariate analysis included the following variables;
hematologic malignancy, neutropenia, biliary tract infection,
central venous catheter, intensive care unit (ICU) stay at time
of culture, nosocomial infection, duration of hospital stay
before bacteremia, monomicrobial infection, E. faecium infec-
tion, and previous use of penicillins, vancomycin, 3rd gen-
eration cephalosporin, aminoglycoside and quinolone. Mul-
tivariate analysis identified neutropenia, monomicrobial bac-
teremia, ICU stay at time of culture and use of 3rd genera-
tion cephalosporin as independent risk factors for bacteremia
caused by enterococci with HLGR (Table 3).
Influence of HLGR on mortality in patients with enterococcal
bacteremia
In univariate analysis, fourteen-day and 30-day mortalities
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*Statistically significant, P≤0.05.
aContinuous variables are expressed as means (±SD); 
bExpressed as
number of deaths/number of patients followed up (%).
HLGR, high-level gentamicin resistance; GI, gastrointestinal; APACHE,
acute physiology and chronic health evaluation; ICU, intensive care unit.
Variables
Number (%) of patients with 
bacteremia due to enterococci
Without HLGR
(n=79)
With HLGR
(n=136)
P value
Demographic data
Male 52 (66) 92 (68) 0.784
Age (yr)
a 58.1±14.2 56.2±16.8 0.389
Underlying disease
Cancer 42 (53) 70 (51) 0.811
Hematologic malignancy 4 (5) 27 (19) 0.003*
Neutropenia 4 (5) 39 (29) <0.001*
Solid organ transplantation 3 (4) 5 (4) >0.999
Hemodialysis 3 (4) 10 (7) 0.382
Urologic disease 5 (6) 7 (5) 0.763
Primary site of infection
Biliary tract 35 (44) 33 (24) 0.002*
GI tract other than biliary tract 13 (16) 35 (26) 0.115
Urinary tract 12 (15) 20 (15) 0.923
Vascular catheter 2 (3) 12 (9) 0.071
Infective endocarditis 6 (8) 3 (2) 0.078
Comorbid or predisposing condition
E. faecium infection 45 (57) 105 (77) 0.002*
Polymicrobial 30 (38) 22 (24) <0.001*
Nosocomial 51 (65) 115 (85) 0.001*
APACHE II score
a 14.4±7.3 20.7±8.3 <0.001*
ICU stay at culture 7 (9) 36 (26) 0.002*
Central venous catheter 10 (5) 41 (29) 0.004*
Hospital-days before blood  16.9±22.8 33.6±47.5 0.004*
culture
Treatment and outcomes
Appropriate antibiotic 52 (66) 88 (65) 0.868
treatment
14-day mortality
b 12/78 (15) 50/135 (37) 0.001*
30-day mortality
b 17/76 (22) 66/133 (50) <0.001*
Table 1. Clinical features of 215 patients with bacteremia caused
by enterococci with or without HLGR
*Statistically significant, P≤0.05.
HLGR, high-level gentamicin resistance.
Variables
Number (%) of patients with 
bacteremia due to enterococci
Without HLGR
(n=79)
With HLGR
(n=136)
P value
Previous antibiotic use
Penicillins 12 (15) 46 (34) 0.003*
3rd generation cephalosporin 42 (53) 110 (81) <0.001*
Aminoglycoside 30 (38) 93 (68) <0.001*
Quinolone 12 (15) 44 (32) 0.006*
Vancomycin 4 (5) 28 (21) 0.002*
Antibiotic resistance
Ampicillin resistance 18 (23) 107 (79) <0.001*
Vancomycin resistance 1 (1) 18 (13) 0.003*
High-level streptomycin  18 (23) 82 (60) <0.001*
resistance
Table 2. Previous antibiotic use and antibiotic resistance in 215
patients with bacteremia caused by enterococci with or without
HLGR
HLGR, High-level gentamicin resistance; ICU, Intensive care unit.
Risk factors Odds ratio (95.0% CI) P value
Neutropenia 6.17 (2.02-18.87) 0.001
Monomicrobial bacteremia 3.04 (1.50-6.17) 0.002
ICU stay at culture 3.44 (1.33-8.91) 0.011
3rd generation cephalosporin use 3.39 (1.74-6.61) <0.001
Table 3. Associated factors for acquisition of bacteremia due
to enterococci with HLGR determined by multivariate analysis
using a logistic regression modelwere significantly higher in patients with bacteremia caused
by enterococci with HLGR than in patients with bacteremia
caused by enterococci without HLGR (37% vs. 15%, P=
0.001; 50% vs. 22%, P<0.001; Table 1).
We performed multivariate analysis with the Cox-regres-
sion model to determine whether the difference in mortality
was due to HLGR. The multivariate analysis included the fol-
lowing variables; biliary tract infection, hematologic malig-
nancy, bone marrow transplantation, neutropenia, cancer che-
motherapy, corticosteroid use, immunosuppressant use, E.
faecium infection, APACHE II score, ampicillin resistance,
vancomycin resistance, high-level gentamicin resistance and
inappropriate antibiotic treatment. The analysis identified
APACHE II score, bone marrow transplantation, corticos-
teroid use and inappropriate antibiotic treatment as indepen-
dent risk factors for 30-day mortality (Table 4). When we
controlled for these factors, the odds ratio for mortality due
to bacteremia caused by enterococci with HLGR compared
with bacteremia caused by enterococci without HLGR was
1.36, which was not statistically significant (95% confidence
interval: 0.75-2.44).
DISCUSSION
Enterococci with HLGR comprised 63% of the enterococcal
isolates that caused clinically significant bacteremia in our
institute. In previous studies, the proportion of HLGR in
blood isolates was 33-62% (7, 8, 10-12). Most isolates with
HLGR were E. faecalis in the 1980s and early 1990s (10, 11).
However, a recent study found almost the same rate of HLGR
in E. faecalis and E. faecium blood isolates (12). HLGR was
prevalent among enterococcal blood isolates in our study, as
in previous studies. However, in our case the frequency of
HLGR was significantly higher in E. faecium than in E. fae-
calis. Our data thus suggest that HLGR is now also prevalent
in E. faecium. This may be due to the increase of multi-drug
resistant E. faecium as the cause of nosocomial bacteremia (1,
18-20).
Some investigators have reported no connection between
HLGR and the severity of the underlying disease or adverse
outcome in enterococcal bacteremia (10, 11). On the other
hand, others have reported higher mortality in patients with
bacteremia caused by enterococci with HLGR (12). In the
present study, we found that bacteremia caused by enterococci
with HLGR was associated with more severe underlying dis-
ease and higher mortality than bacteremia caused by entero-
cocci without HLGR. There are two possible explanations
for the discrepancy between the studies. First, the predomi-
nant isolate differed; most of the blood isolates in the previ-
ous studies were E. faecalis, whereas the predominant blood
isolate in our study was E. faecium. Although we observed the
effects of HLGR on clinical features and outcomes in both
E. faecium and E. faecalis, the differences were more prominent
in E. faecium (data not shown). Second, it is possible that the
sample sizes in the previous studies were too small to reveal
the differences.
In previous studies, independent risk factors for the acquisi-
tion of bacteremia due to enterococci with HLGR were inten-
sive care unit stay, previous use of antibiotics, especially broad-
spectrum cephalosporin, chronic renal failure and E. faecalis
species (8, 11). The results of our study are consistent with
these findings; however, E. faecalis species was not a risk fac-
tor in our study. Two kinds of patients were at especially high
risk of acquiring infections with HLGR enterococci in our
study: patients with neutropenia and patients with intensive
care unit stay. Our data suggest that the judicious use of 3rd
generation cephalosporin is important to reduce infections
caused by enterococci with HLGR, especially in patients
belonging to these two groups.
There has been controversy over whether HLGR influences
the prognosis of patients with enterococcal bacteremia. Wata-
nakunakorn et al. and Caballero-Granado et al. reported that
HLGR did not influence crude mortality from enterococcal
bacteremia in 178 and 93 cases, respectively (10, 11). Shaked
et al., however, recently reported that HLGR was an inde-
pendent risk factor for mortality in 117 patients with ente-
rococcal bacteremia (12). However, HLGR was associated
with more severe underlying disease, resistance to other antibi-
otics and many comorbid conditions. Therefore confounding
factors would need to be corrected for by an appropriate sta-
tistical model and an adequate sample size. It is possible that
the sample size in the latter study was too small for the con-
founding factors to have been adequately corrected for in the
multivariate analysis. In any event, in our study, which in-
volved more cases than the previous studies, we found that
HLGR did not significantly influence the outcome of ente-
rococcal bacteremia.
The anatomical site of infection should be taken into account
in treating enterococcal infection, because the appropriate
treatment strategy differs for different sites. In cases of endo-
carditis or meningitis, combination therapy with a cell-wall
active agent plus an aminoglycoside should be employed (4,
21). Antibiotic use in enterococcal infections without endo-
carditis or meningitis has been questioned because enterococci
are traditionally considered to be pathogens of low virulence
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*Per 1 point increase in score.
APACHE, Acute physiology and chronic health evaluation.
Risk factors Odds ratio (95.0% CI) P value
Increasing APACHE II score* 1.08 (1.06-1.10) <0.001
Bone marrow transplantation 4.27 (2.03-8.99) <0.001
Corticosteroid use 2.30 (1.38-3.82) 0.001
Inappropriate antibiotic treatment 2.35 (1.49-3.70) <0.001
Table 4. Independent risk factors for 30-day mortality in 209 epi-
sodes of enterococcal bacteremia, as determined by survival
analysis using the Cox-regression model(22). However, there is some evidence that appropriate anti-
biotic use is associated with improved outcome in patients
with enterococcal bacteremia (13). Combination therapy with
a cell-wall active agent plus an aminoglycoside has also been
considered in enterococcal bacteremia without endocarditis
(5, 6), but in a number of studies there was no statistically
significant difference in outcome between monotherapy and
combination therapy (10, 23-25).
In our study, most of the cases were of enterococcal bac-
teremia without endocarditis or meningitis, and appropri-
ate antibiotic treatment was associated with improved out-
come. However, we also failed to obtain evidence that com-
bination therapy was more effective. When we performed a
multivariate analysis on 131 patients with enterococcal bac-
teremia without endocarditis who had received appropriate
antibiotic treatment, monotherapy did not emerge as an inde-
pendent risk factor for 30-day mortality (95% confidence
interval: 0.72-5.79; P=0.180). It appears that prognosis of
enterococcal bacteremia may be improved by appropriate
antibiotic treatment rather than by giving combination anti-
biotic therapy.
Our study has some limitations. First, since it was retro-
spective in design, confounding factors which can affect mor-
tality were not uniformly controlled. Because the factors in-
fluencing the physicians’ choice of antibiotics were not deter-
mined, they may have influenced our results as unmeasured
confounding factors in the analysis. Second, we did not per-
form molecular epidemiologic studies such as pulsed-field
gel electrophoresis to exclude outbreaks of specific strains or
common sources of infection. Third, this was a single-center
study and factors such as the rate of referrals or surgery for
complex disorders could have impacted the results.
In conclusion, patients with HLGR enterococcal bacteremia
were more likely to have severe underlying diseases and were
associated with higher mortality than patients with non-HL-
GR enterococcal bacteremia. However, HLGR itself did not
influence mortality in enterococcal bacteremia.
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